FRANKLIN, TN--(Marketwired - Jul 16, 2013) - M*Modal, a leading provider of clinical documentation and Speech Understanding™ solutions, today announced its M*Modal Fluency Direct™ front-end speech (FES) software is included in the KLAS Research customer rankings. M*Modal's cloud-based platform debuts with exceptional scores across all KLAS Speech Recognition category metrics, based on healthcare information technology (HIT) customer feedback.

"We are extremely proud to see our solution receive such a positive response from customers," said Duncan James, CEO of M*Modal. "M*Modal Fluency Direct was designed from the ground up to specifically serve the healthcare industry, and leverages cloud computing for anytime, anywhere access. These features really differentiate our Speech Understanding platform, and we are pleased that our technology is receiving such significant acceptance by users."

Fluency Direct captures spoken dictation from physicians and clinicians and instantly populates electronic health record systems with patient data. M*Modal's solution makes clinical documentation painless and productive by enabling doctors to conversationally create and edit patient narratives directly within system templates. Physicians can capture richer information quickly and efficiently, resulting in more complete clinical documentation, increased productivity and better patient care.

According to KLAS findings, in its debut M*Modal Fluency Direct has received outstanding scores in all areas of the KLAS Speech Recognition category, including Sales and Contracting, Implementation and Training, Functionality and Upgrades, Service and Support, and General. Surveyed providers praised M*Modal Fluency, and it was reported that 100% of current customers would purchase M*Modal Fluency Direct again and the technology is part of their long term plans. For example, one CIO stated:

"Our experience with M*Modal has been absolutely wonderful. They are fantastic to work with. I knew the adoption of their product would be good, but the adoption is beyond what I imagined. Our specialties want it now, so that is running really well. My users are asking me for more templates on the natural language processing engine. M*Modal's development and design teams have been stellar." - CIO

"We are excited and grateful to our customers for trusting us with their clinical documentation needs, and we will continue to bring them the best possible technology, service and support," James said.

Unlike other speech recognition technologies, M*Modal Fluency products use a single underlying speech platform, giving each physician access to his/her trained voice profile across any application. In addition, M*Modal's solutions offers strong medically tuned speech recognition by capturing and processing the documentation of more than 200,000 clinicians every day, for deep recognition of sophisticated medical terminologies, speech dialects, accents and cadences.

For more information on M*Modal please visit www.mmodal.com or follow on Twitter @MModal.

Collected about M*Modal Fluency Direct by KLAS in July 2013 © KLAS Enterprises, LLC. All rights reserved. www.KLASresearch.com

About M*Modal
M*Modal is a leading healthcare technology provider of advanced clinical documentation solutions, enabling hospitals and physicians to enrich the content of patient electronic health records (EHR) for improved healthcare and comprehensive billing integrity. As one of the largest clinical transcription service provider in the U.S., with a global network of medical editors, M*Modal also provides advanced cloud-based Speech Understanding™ technology and data analytics that enable physicians and clinicians to include the context of their patient narratives into electronic health records in a single step, further enhancing their productivity and the cost-saving efficiency and quality of patient care at the point of care. M*Modal has been recognized as one of the fastest growing technology companies in North America, placing in the top third of Deloitte's Technology Fast 500 for 2012. For more information, please visit Twitter, Facebook and YouTube.